298 related articles for article (PubMed ID: 12477969)
1. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
[TBL] [Abstract][Full Text] [Related]
2. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Nagai Y; Yao L; Kobori H; Miyata K; Ozawa Y; Miyatake A; Yukimura T; Shokoji T; Kimura S; Kiyomoto H; Kohno M; Abe Y; Nishiyama A
J Am Soc Nephrol; 2005 Mar; 16(3):703-11. PubMed ID: 15647337
[TBL] [Abstract][Full Text] [Related]
3. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Yamagishi S; Koga K; Inagaki Y; Amano S; Okamoto T; Takeuchi M
Drugs Exp Clin Res; 2002; 28(6):221-7. PubMed ID: 12776575
[TBL] [Abstract][Full Text] [Related]
4. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M
J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats.
Kaihara M; Nakamura Y; Sugimoto T; Uchida HA; Norii H; Norii H; Hanayama Y; Makino H
Acta Med Okayama; 2009 Feb; 63(1):35-42. PubMed ID: 19247421
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus.
Uehara Y; Hirawa N; Kawabata Y; Numabe A; Gomi T; Ikeda T; Omata M
Am J Hypertens; 1999 Jan; 12(1 Pt 1):21-7. PubMed ID: 10075380
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
9. Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Tomiyoshi Y; Sakemi T; Aoki S; Miyazono M
Nephron; 2002 Dec; 92(4):860-7. PubMed ID: 12399633
[TBL] [Abstract][Full Text] [Related]
10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
11. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
Okada M; Takemura T; Yanagida H; Yoshioka K
Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
[TBL] [Abstract][Full Text] [Related]
12. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Sofue T; Kiyomoto H; Kobori H; Urushihara M; Nishijima Y; Kaifu K; Hara T; Matsumoto S; Ichimura A; Ohsaki H; Hitomi H; Kawachi H; Hayden MR; Whaley-Connell A; Sowers JR; Ito S; Kohno M; Nishiyama A
Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
[TBL] [Abstract][Full Text] [Related]
13. Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats.
Taniguchi M; Kim S; Zhan Y; Iwao H
Hypertens Res; 2002 Mar; 25(2):287-94. PubMed ID: 12047045
[TBL] [Abstract][Full Text] [Related]
14. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
[TBL] [Abstract][Full Text] [Related]
15. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Kikuchi Y; Yamada M; Imakiire T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Oda T; Suzuki S; Miura S
J Endocrinol; 2007 Mar; 192(3):595-603. PubMed ID: 17332527
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
17. Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats.
Aoyama I; Shimokata K; Niwa T
Am J Nephrol; 2000; 20(3):232-41. PubMed ID: 10878408
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.
Li C; Yang CW; Park CW; Ahn HJ; Kim WY; Yoon KH; Suh SH; Lim SW; Cha JH; Kim YS; Kim J; Chang YS; Bang BK
Kidney Int; 2003 Feb; 63(2):454-63. PubMed ID: 12631111
[TBL] [Abstract][Full Text] [Related]
19. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
[TBL] [Abstract][Full Text] [Related]
20. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
